Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

Author(s):
Manns, M.; Samuel, D.; Gane, E.J.; Mutimer, D.; McCaughan, G.; Buti, M.; Prieto, M.; Calleja, J.L.; Peck-Radosavljevic, M.; Mullhaupt, B.; Agarwal, K.; Angus, P.; Yoshida, E.M.; Colombo, M.; Rizzetto, M.; Dvory-Sobol, H.; Denning, J.; Arterburn, S.; Pang, P.S.; Brainard, D.; McHutchison, J.G.; Dufour, J.F.; Vlierberghe, H. van; Hoek, B. van (0000-0001-6527-764X); Forns, X.; SOLAR-2 Investigators
Published
2016
Publication type
Article / Letter to editor

Abstract

Interpretation Ledipasvir-sofosbuvir and ribavirin provided high rates of SVR12 for patients with advanced liver disease, including those with decompensated cirrhosis before or after liver transplantation.

Date issued
2016-06-01
Language
English
Publisher
ELSEVIER SCI LTD
Is part of
The Lancet Infectious Diseases (2016), Vol. 16, no. 6, p. 685-697
hdl
1887/117202
doi
10.1016/S1473-3099(16)00052-9